JMJohn D. Matthews

John D. Matthews

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John D. Matthews has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Maurizio Fava

    3 shared publications
  • Adrienne O. Ba van Nieuwenhuizen

    From the Inpatient Psychiatric Services, and †Depression Clinical and Research Program, Harvard Medical School, Massachusetts General Hospital Boston, MA

    1 shared publication
  • Adrienne O. van Nieuwenhuizen

    1 shared publication
  • Caitlin Ba Homberger

    From the Inpatient Psychiatric Services, and †Depression Clinical and Research Program, Harvard Medical School, Massachusetts General Hospital Boston, MA

    1 shared publication
  • Caleb J. Siefert

    1 shared publication
  • Caleb Siefert

    From the Inpatient Psychiatric Services, and †Depression Clinical and Research Program, Harvard Medical School, Massachusetts General Hospital Boston, MA

    1 shared publication

Latest Publications

  • A Double-blind, Placebo-Controlled Study of the Impact of Galantamine on Anterograde Memory Impairment During Electroconvulsive Therapy

    by John D. Matthews, Caleb J. Siefert, Mark A. Blais, Lawrence T. Park, Charles A. Welch, Christina M. DuBois, Adrienne O. van Nieuwenhuizen, Kathryn O. Rooney, Rita C. Seabrook, Lauren E. Durham, et al.

    Electroconvulsive therapy (ECT) continues to be an effective treatment option for patients who fail to respond to pharmacological interventions, are unable to tolerate medications, and show a suboptimal response to behavioral and psychotherapeutic treatments. However, risks for cognitive impairment may contribute to some patients' refusal of ECT. The present study examined galantamine as a pharmacological intervention to reduce cognitive adverse effects from ECT. Thirty-nine inpatients diagnosed with major depressive disorder; bipolar disorder, depressed type; or schizoaffective disorder, depressed type and admitted for ECT were randomized to galantamine or placebo. Study drugs were initiated 24 to 48 hours before starting ECT and continued throughout the course of ECT. A neuropsychological test battery was administered at baseline and 24 to 48 hours after completing a course of ECT treatments. Depression severity was monitored using the 17-item Hamilton Rating Scale for Depression and Clinical Global Impression Scale at baseline, weekly, and end point. Self-rated adverse effects were monitored weekly. Thirty participants (12 patients in the galantamine group, 18 patients in the placebo group) had both pretreatment and posttreatment neuropsychological ratings. Those in the galantamine group scored significantly higher at discharge for delayed memory (t28 = 2.44, P < 0.05). Hierarchical regressions examined if treatment condition predicted changes in delayed memory scores from baseline to discharge. Inclusion of the treatment condition in the final model made a significant incremental improvement in prediction (ΔR = 0.12, F1,27 change = 4.65, P < 0.05; β = 0.37, t = 2.16, P < 0.05). Galantamine was well tolerated with no clinically significant bradycardia or prolonged paralysis when administered with ECT. Galantamine may be protective against impairment in retention of new learning. Galantamine exhibited minimal adverse effects and was safe when administered during ECT. The present findings require replication by future researchers using larger samples before broad conclusions can be drawn.


  • An Open Study of Aripiprazole and Escitalopram for Psychotic Major Depressive Disorder

    by John D. Md Matthews, Caleb Siefert, Christina Dording, John W. Denninger, Lawrence Park, Adrienne O. Ba van Nieuwenhuizen, Katherine Ba Sklarsky, Sarah Bs Hilliker, Caitlin Ba Homberger, Kathryn Ba Rooney, et al.

    Objective: This 7-week trial assessed the efficacy and tolerability of aripiprazole combined with escitalopram in the acute treatment of major depressive disorder, with psychotic features (MD-Psy). Methods: Sixteen male and female patients with a Diagnostic Statistical Manual of Mental Disorders, Fourth Edition, diagnosis of MD-Psy were recruited for this study from September 13, 2004 to August 9, 2006. Escitalopram and aripiprazole were flexibly dosed for 7 weeks, with maximum dosages of 20 and 30 mg/d, respectively. The 17-item Hamilton Rating Scale for Depression (HAM-D-17) and Structured Clinical Interview for DSM-IV psychosis module were used to measure depression and psychosis responses. The Barnes Akathisia Scale and the Simpson Angus Scale were used to assess for akathisia and extrapyramidal symptoms. Results: Thirteen of the 16 subjects completed the study. The MD-Psy response rate (50% or greater drop in HAM-D-17 and no psychosis) (intent-to-treat, last observation carried forward) was 62.5%, and the MD-Psy remission rate (HAM-D-17, <8, and no psychosis) (intent-to-treat, last observation carried forward) was 50.0%. Ten of the 16 subjects developed akathisia; however, 9 of the 10 subjects had resolution or partial resolution of akathisia with dose adjustment or treatment with propranolol. Conclusions: The combination of escitalopram and aripiprazole seems to be an effective and safe treatment for MD-Psy.


  • An Open Study of Olanzapine and Fluoxetine for Psychotic Major Depressive Disorder

    by John D. Matthews, Kathryn A. Bottonari, Laura M. Polania, David Mischoulon, Christina M. Dording, Robert Irvin, Maurizio Fava

    From The Journal of Clinical Psychiatry: